FGEN Insider Trading
Insider Ownership Percentage: 1.98%
Insider Buying (Last 12 Months): $164,133.91
Insider Selling (Last 12 Months): $0.00
FibroGen Share Price & Price History
Current Price: $0.33
Price Change: ▲ Price Increase of +0.0118 (3.76%)
As of 04/28/2025 05:00 PM ET
FibroGen Insider Trading History
FibroGen Institutional Trading History
Data available starting January 2016
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Read More on FibroGen
Volume
420,933 shs
Average Volume
2,243,386 shs
Market Capitalization
$32.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.87
Who are the company insiders with the largest holdings of FibroGen?
FibroGen's top insider investors include:
- Thane Wettig (CEO)
- Enrique A Conterno (CEO)
- James A Schoeneck (Director)
- Christine Chung (SVP)
- Mark Eisner (EVP)
- Thane Wettig (Insider)
- Deyaa Adib (Insider)
- Juan Graham (CFO)
- Jeffrey William Henderson (Director)
- Benjamin Cravatt (Director)
Learn More about top insider investors at FibroGen.